SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation regarding Regulatory Order11-06-2024
11-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Intimation of Schedule of Analyst/Institutional Investor Meeting11-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation regarding loss of share certificates09-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation regarding Acquisition06-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Regulatory Order
Intimation regarding Statutory order04-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Nidlegy MAA submitted to EMA04-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on June 03, 2024 for Raksha Sudhir Valia04-06-2024
Sun Pharma expects high single-digit top line growth in the current fiscal: MD
The Mumbai-based firm reported a consolidated total revenue from operations at 48,497 crore for FY24.02-06-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Result of Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 202431-05-2024
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation under Regulation 30 - Acquisition30-05-2024